CJC+Ipamorelin 10mg

Description

• Synergistic Growth Hormone (GH) Release: Investigating how the dual activation of the Growth Hormone-Releasing Hormone (GHRH) receptor (via CJC-1295) and the Ghrelin/Growth Hormone Secretagogue receptor (via Ipamorelin) produces a amplified, pulsatile GH release.

• Adipose Tissue Metablism & Lipolysis: Evaluating the combined impact of elevated growth hormone cascades on lipid oxidation, free fatty acid mobilization, and the reduction of deep visceral adipose tissue (VAT).

• Musculoskeletal Regeneration & IGF-1 Expression: Studying how continuous, pulsatile growth hormone secretion promotes hepatic IGF-1 synthesis to stimulate muscle cell proliferation, nitrogen retention, and connective tissue repair.

• Selective Pituitary Somatotroph Stimulation: Analyzing the safety and regulatory patterns of the pituitary gland when stimulated without elevating secondary stress hormones like cortisol, ACTH, or prolactin.

• Bone Density & Mineralization Pathways: Probing the potential of dual secretagogue administration to enhance osteoblast activity and counteract age-related or glucocorticoid-induced bone mineral decline.